Background: Estrogens are essential for the growth of breast cancer in the case of
premenopausal as well as in postmenopausal women. However, most of the breast cancer
incidences are reported in postmenopausal women and the concurrent risk surges with an
increase in age. Since the enzyme aromatase catalyses essential steps in estrogen
biosynthesis, Aromatase Inhibitors (AIs) are effective targeted therapy in patients with
Estrogen Receptor positive (ER+) breast cancer. AIs are more effective than Selective …